|
Cholesteryl Ester Transfer Protein Deficiency
|
0.320 |
GermlineCausalMutation
|
disease |
ORPHANET |
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.
|
2022742 |
1991 |
|
Apolipoprotein C-III Deficiency
|
0.610 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
APOLIPOPROTEIN C-III, NONGLYCOSYLATED PHENOTYPE
|
0.100 |
CausalMutation
|
phenotype |
CLINVAR |
|
|
|
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mixed dyslipidemia, characterized by elevated triglyceride and apoC-III levels and low HDL cholesterol level, with or without elevated LDL cholesterol, increases cardiovascular disease risk and is commonly treated with combined statin and fibrate therapy.
|
22236405 |
2012 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A high level of APOC3 expression is an independent risk factor for some lipid metabolism-related diseases, such as cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and atherosclerosis (AS).
|
29555504 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Multiple studies confirmed the correlation between increased apoC-III levels and cardiovascular disease.
|
29547399 |
2018 |
|
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It is effective in decreasing triglycerides by targeting apoC3 levels in patients with coronary heart disease.
|
30511426 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease.
|
31329855 |
2019 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MS patients with CAD had significantly higher apoC-III levels than did CAD-free MS patients.
|
14563827 |
2003 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It is effective in decreasing triglycerides by targeting apoC3 levels in patients with coronary heart disease.
|
30511426 |
2019 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease.
|
31329855 |
2019 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ApoC-III levels were significantly associated with CAD risk (odds ratio, 1.91; 95% confidence interval, 1.48-2.48 for highest compared with lowest quintile), retaining significance after adjustment for traditional CAD risk factors (odds ratio, 1.47; 95% confidence interval, 1.11-1.94).
|
28473441 |
2017 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, elevated apoC-III levels have been associated with metabolic syndrome and type 2 diabetes mellitus.
|
23542898 |
2013 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
ApoC-III levels were significantly increased in MS patients, and the probability of having MS was correlated with increasing quartiles of apoC-III levels.
|
14563827 |
2003 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.270 |
AlteredExpression
|
disease |
BEFREE |
In the DCCT/EDIC cohort of patients, there was an independent positive association of apoCIII level with microvascular complications of Type 1 diabetes.
|
15642486 |
2005 |
|
Hyperlipidemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The development of hyperlipidemia in acne patients treated with retinoic acid (RA) has been attributed to the induction of apolipoprotein C-III expression.
|
24234421 |
2014 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, AR ameliorated atherosclerosis via the regulation of hepatic lipid metabolism, and AR also contributed to the activation of PPAR-alpha, APOA1, APOA2 and APOC3.
|
25979856 |
2015 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our observations demonstrate that relative insulin deficiency increases APOC3 and that this results in elevated levels of TRLs and accelerated atherosclerosis in a mouse model of T1DM.
|
31295146 |
2019 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A high level of APOC3 expression is an independent risk factor for some lipid metabolism-related diseases, such as cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and atherosclerosis (AS).
|
29555504 |
2018 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A high level of APOC3 expression is an independent risk factor for some lipid metabolism-related diseases, such as cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and atherosclerosis (AS).
|
29555504 |
2018 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our observations demonstrate that relative insulin deficiency increases APOC3 and that this results in elevated levels of TRLs and accelerated atherosclerosis in a mouse model of T1DM.
|
31295146 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, AR ameliorated atherosclerosis via the regulation of hepatic lipid metabolism, and AR also contributed to the activation of PPAR-alpha, APOA1, APOA2 and APOC3.
|
25979856 |
2015 |
|
Coronary heart disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ApoC-III levels determined the development of diabetes [RR 1.56 (95%CI 1.21; 2.01)] and CHD [RR 1.38 (1.10; 1.72) for an increment of 14%], after adjustment for confounders.
|
21185820 |
2011 |
|
Coronary heart disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease.
|
31329855 |
2019 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ApoC-III levels determined the development of diabetes [RR 1.56 (95%CI 1.21; 2.01)] and CHD [RR 1.38 (1.10; 1.72) for an increment of 14%], after adjustment for confounders.
|
21185820 |
2011 |